The first patient with blood cancer has been successfully treated with the new Russian drug Utzhefra, RIA Novosti was informed by the press service of the National Medical Center of Hematology of the Russian Ministry of Health. “The first patient - a participant in the clinical trial - is a 59-year-old woman, she received “Utzhefra” on December 12 and 13 with two doses ... After the introduction of “Utzhefra” the patient had no serious complications, after a week of observation in the intensive care unit, which is stipulated by the study protocol, she was transferred to the hematology department and further observed in a day hospital,” - said the principal investigator, head of the department of cellular and immune therapy NMIC of hematology of the Ministry of Health of Russia Olga Aleshina. It is noted that the results of the examination confirmed a complete response to therapy and the safety of the drug. A total of 60 patients will take part in the study, within a year after the drug administration they will undergo examinations, blood tests, as well as instrumental studies to determine the status of the underlying disease and remission control. Alyoshina announced the start of a clinical trial of the Russian drug in November last year.